While working to develop an AKI drug treatment, though, the University of Arizona team treated an AKI mouse model with lasmiditan. They found that the migraine drug stimulated the recovery of kidney function.
This included reduced fibrosis, reduced proximal tubule damage, improved vascular integrity, and mitochondrial biogenesis– or the cellular process responsible for producing new mitochondria depending upon physiological and environmental changes.
So, since the FDA has already approved lasmiditan, the study’s lead author Rich Schnellmann, Ph.D., believes it could easily be repurposed for AKI cases.
Further research is warranted before then. But, Schnellman is confident that the study’s results are promising and point to an AKI treatment on the horizon.
To read the study’s complete findings, which have since been published in the American Journal Of Physiology, visit the link here.
If true crime defines your free time, this is for you: join Chip Chick’s True Crime Tribe